VERA
HEALTHCAREVera Therapeutics Inc - Class A
$36.59+2.08 (+6.01%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VERA Today?
No stock-specific AI insight has been generated for VERA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$18.76$56.05
$36.60
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-4.66
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume825K
Avg Volume (10D)—
Shares Outstanding71.7M
VERA News
22 articles- Ten new hires get Vera stock awards tied to 60,375 sharesStock Titan·May 8, 2026
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire·May 8, 2026
- Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care ConferenceYahoo Finance·May 4, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price SurgeYahoo Finance·Apr 10, 2026
- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightGlobeNewswire Inc.·Apr 6, 2026
- These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target247 Wall St·Apr 1, 2026
- Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal OfficerYahoo Finance·Mar 25, 2026
- High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest HoldingMotley Fool·Mar 21, 2026
- This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should KnowMotley Fool·Mar 21, 2026
- This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should KnowMotley Fool·Mar 21, 2026
- Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems BullishMotley Fool·Mar 21, 2026
- This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This YearMotley Fool·Mar 20, 2026
- This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million InvestmentMotley Fool·Mar 16, 2026
- This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in StockMotley Fool·Mar 16, 2026
- This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA DecisionMotley Fool·Mar 13, 2026
- Vera Therapeutics Appoints Christopher Hite to Board of DirectorsYahoo Finance·Mar 5, 2026
- Does FDA Priority Review And Phase 3 Win For Atacicept Redefine The Bull Case For Vera (VERA)?Yahoo Finance·Feb 27, 2026
- Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial ResultsYahoo Finance·Feb 26, 2026
- Vera Therapeutics to Participate at Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief AppointmentYahoo Finance·Feb 19, 2026
All 22 articles loaded
Price Data
Open$35.60
Previous Close$34.52
Day High$36.01
Day Low$34.04
52 Week High$56.05
52 Week Low$18.76
52-Week Range
$18.76$56.05
$36.60
Fundamentals
Market Cap$2.6B
P/E Ratio—
EPS$-4.66
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume825K
Avg Volume (10D)—
Shares Outstanding71.7M
About Vera Therapeutics Inc - Class A
Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—